Drugs for treatment of very high blood pressure during pregnancy

Duley, Lelia; Dj, Henderson-Smart

doi:10.1002/14651858.cd001449

Cited by 57 publications

(56 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most recent Cochrane review found no good evidence that one short acting antihypertensive is better than another, with the exception of ketanserin, which is associated with more persistent hypertension 53. The Cochrane inclusion and exclusion criteria differed somewhat from those in this study, but the most important difference seems to be in the reviews' methods.…”

Section: Discussioncontrasting

confidence: 63%

Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis

Magee

2003

BMJ

371

161

View full text Add to dashboard Cite

Objective To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy. Study design Meta-analysis of randomised controlled trials (published between 1966 and September 2002) of short acting antihypertensives for severe hypertension in pregnancy. Independent data abstraction by two reviewers. Data were entered into RevMan software for analysis (fixed effects model, relative risk and 95% confidence interval); in a secondary analysis, risk difference was also calculated. Results Of 21 trials (893 women), eight compared hydralazine with nifedipine and five with labetalol. Hydralazine was associated with a trend towards less persistent severe hypertension than labetalol (relative risk 0.29 (95% confidence interval 0.08 to 1.04); two trials), but more severe hypertension than nifedipine or isradipine (1.41 (0.95 to 2.09); four trials); there was significant heterogeneity in outcome between trials and differences in methodological quality.

show abstract

Section: Discussioncontrasting

confidence: 63%

Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis

Magee

2003

BMJ

371

161

View full text Add to dashboard Cite

show abstract

“…They always did a meta-analysis [9,12,17,19-25,27-40,44-46] where applicable. This is reassuring for clinicians who rely on them for decision-making.…”

Section: Discussionmentioning

confidence: 99%

“…Majority of the reviews were on hypertensive disorders [8,10,11,17,19-23,31-34,37,48,53,55,58,64,65,69,70], psychiatry [15,27,43,47,50-52,56,57,59,61,74,75], or thromboembolism [26,42,62-66,68]. Even among these commonly addressed areas, a very narrow spectrum of diseases was covered.…”

Section: Discussionmentioning

confidence: 99%

A review of the methodological features of systematic reviews in maternal medicine

Sheikh

Johnston

Thangaratinam

et al. 2007

BMC Med

View full text Add to dashboard Cite

Background: In maternal medicine, research evidence is scattered making it difficult to access information for clinical decision making. Systematic reviews of good methodological quality are essential to provide valid inferences and to produce usable evidence summaries to guide management. This review assesses the methodological features of existing systematic reviews in maternal medicine, comparing Cochrane and non-Cochrane reviews in maternal medicine.

show abstract

“…Best avoided are diazoxide at high doses, since it is associated with a greater risk of hypotension and caesarean section than labetalol, and the serotonin receptor antagonist ketanserin, which led to far more persistent hypertension than hydralazine 13. An alternative analysis suggested avoiding hydralazine as first line treatment14 but this review included quasi-random designs and pooled studies comparing hydralazine with various drugs, regardless of whether they were likely to be better or worse.…”

Section: Primary Prevention Of Pre-eclampsiamentioning

confidence: 99%